Introduction
The cure rates in childhood ALL have increased from 10% to 80% over the last three decades. This has been possible by improved diagnostics, identification of risk factors and intensification of the risk-directed therapy. Current chemotherapy treatment protocols induce complete remission (CR) in Ͼ95% of children with ALL and disease-free survival (DFS) rates are exceeding 70%. [1] [2] [3] [4] [5] The patients are considered to be in morphological remission when blast cells compose less than 5% of the bone marrow (BM) cell population. However, relapses of disease do occur, suggesting that some of the leukemic blasts are resistant to chemotherapy and can persist in very small amounts in the BM. These blasts are called minimal residual disease (MRD). [6] [7] [8] There are several methods of monitoring MRD in acute leukemia. Leukemic cells can be distinguished from normal hematopoietic cells on the basis of chromosomal or molecular abnormalities, antigen receptor gene rearrangements and immunophenotype (reviewed in Refs 9-11). Reciprocal chromosomal translocations are identified in only a minority of cases in childhood ALL. 12, 13 Therefore, IgH or TcR rearrangement studies by molecular methods (Southern Blot or PCR) have been most widely applied. Traditional PCR-based methods may have a higher sensitivity but need to improve in quantitation. 11, 14, 15 with application of real-time quantitative PCR is now under evaluation. 16 Immunophenotyping with flow cytometry offers an MRD detection tool that can easily be applied in clinical practice. [17] [18] [19] FC provides quantitative evaluation of cell subsets expressing various phenotypes and discrimination between viable and apoptotic/dead cells. 20 Many cells can be measured quite easily and fast.
Previous studies have pointed out the clinical significance of MRD detection. 14, 17, [21] [22] [23] [24] Sensitive techniques to detect MRD may allow better estimates of the leukemia burden and help to select appropriate therapeutic strategies. The polymerase chain reaction (PCR)-based methods for MRD followup are very sensitive (detecting one leukemic cell in 10 4 to 10 6 BM cells), but they are also laborious and time-consuming.
9,25
Some studies suggest that these methods may have sensitivity higher than clinically relevant cut-off limits, since molecular signs suggesting residual leukemia may be detected even in patients who are in continuous CR (CCR) for a long time after the end of treatment. 26 FC detection of MRD is based on the identification of immunophenotypes expressed on leukemic cells, but not on normal hematopoietic cells. Several studies have been published, investigating immunologic profiles of lymphoid cell subsets in normal BM. [27] [28] [29] [30] [31] [32] [33] That knowledge makes it possible to determine the aberrant phenotypes at diagnosis and to choose the marker combinations to be applied in the followup samples. Detection of MRD with multiparameter FC is well-suited for clinical investigations due to the rapidity and wide availability of methodology. 10, 34 However, in large series of patients from St Jude Hospital, Memphis, TN, USA, flow cytometric detection of MRD with three-color analysis could only be applied in approximately 60% of cases. 23, 35 The frequency of detectable aberrant phenotypes using three-and four-color analysis has recently been reported as over 90% by the same and other groups. 17, 18, 31 An early MRD detection in leukemia patients can increase the possibility to predict risk for relapse and perhaps to select patients who would benefit from more intensified treatment or, even more interestingly, less intensive treatment. The goal of this study was first to characterize the specific aberrant patterns of antigen expression in ALL and to evaluate if the patterns found were suitable for MRD detection. We determined the sensitivity levels by which the leukemic cells could be detected in followup samples obtained from a similarly treated cohort of consecutive patients with childhood ALL. Another goal was to find prognostic levels of MRD for which the effect of changes in treatment intensity could be tested in future protocols.
Patients, materials and methods

Patients and samples
Between 1 July 1994 and 30 June 1998, a total of 70 children were diagnosed with ALL at Karolinska Hospital, Stockholm and consecutively included in the study. The study was approved by the local Ethics Committee at Karolinska Hospital. The cohort consisted of 34 boys and 36 girls between 2 months and 16 years of age (mean 4.4, median 4.5 years). Diagnosis of ALL was made on the basis of morphological evaluation of May-Grü nwald-Giemsa-stained BM smears. 36 The immunologic classification was based on well-established criteria. 37 There were 59 B precursor ALL (four null ALL, 48 common (c)-ALL and seven pre-B-ALL) and 11 T-ALL. The leukemic blasts in 68/70 patients (97%) had at least one aberrant immunophenotype feature that could be followed by FC. In 79% of patients there were two or more aberrant patterns to follow.
Cytogenetic analysis was performed at the Department of Clinical Genetics, Karolinska Hospital. Hyperdiploidy in 11 patients and in one patient the t(12;21) translocation was found (favorable group). Eighteen patients showed a complex karyotype and in two patients the t(9;22) translocation was detected (unfavorable group). Normal karyotype was found in 24 patients (intermediate group). Karyotype analysis was not successful in 11 patients. All three infants with null-ALL showed the t(4;11) translocation.
At follow-up the morphological remission was diagnosed if the BM differential count revealed not more than 5% blasts. The results of MRD analyses were not available for the clinicians and did not influence therapeutic decisions.
Nine patients were excluded from the statistical analysis for the following reasons:
• One patient (risk-group SR, c-ALL) moved back abroad since he was in Sweden only for the first induction treatment.
• Another patient with T-ALL (risk-group HR/VHR) at diagnosis had a relapse under treatment with AML phenotype (see Discussion).
• Two patients (risk-group HR/VHR, c-ALL) received allogeneic BM transplantation in first remission due to t(9;22) and thus were subjected to different treatment. These two patients are still in remission 38 and 42 months after diagnosis.
• Three patients with infant null-ALL (risk-group HR/VHR) are described separately due to the different treatment protocol (see below).
• Two patients (risk-group SR and IR, c-ALL) were not followed by FC, due to uninformative immunophenotype at diagnosis. Neither of these patients suffered relapse.
There were 61 patients included in the statistical analysis. Median observation time for patients who remain in CCR is 53 months. Relapse of ALL was demonstrated in nine of 61 patients (14.75%). One patient suffered relapse during treatment and eight patients after treatment. Two of nine relapses were extra-medullary (testis) with no simultaneous BM relapse. In one of these patients the second relapse occurred in the BM. Median disease-free survival time for patients with recurrent leukemia was 39 months. Two more relapses occurred in the infant ALL-group (two of three patients (66%), see below).
Treatment protocol
All patients were treated according to the NOPHO-92 protocols. 3, 38 Twenty-nine patients were treated according to the standard risk (SR) protocol, 21 to intermediate risk (IR) and 20 to high risk/very high risk (HR/VHR) protocols. Three infants Leukemia with null-ALL were treated according to the separate protocols for infant ALL. The total duration of therapy was 2.5 years for SR, 2 year for IR, HR and VHR risk groups. The treatment protocols for various risk-groups and the timing of follow-up samples depending on the treatment protocol are given in Figure 1 .
Flow cytometry Monoclonal antibody (Mab) panels:
This study was conducted as a part of the BIOMED I Concerted Action 'Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation'. Since the beginning of the study (July 1994) a standardized protocol of triple Mab combinations was applied at diagnosis. 30, 32, 39 If aberrant patterns were found according to the 'empty space' concept described in the BIOMED I Concerted Action publications, the same Mab combinations were used at follow-up (Table 1) . 30, 32, 39 In cases of ALL with aberrant expression of myeloid markers new triple combinations were tailored, dependent on phenotype. In each follow-up sample two Mab combinations: CD14/Glycophorin A (GPA)/CD45 and CD19/CD33/CD3 were also applied to determine B cell, T cell and erythropoietic precursor content. The following antibodies were used: FITC-conjugated: CD3, CD7, CD10, CD19, CD22, CD34, PE-conjugated CD4, CD5, CD38, PerCP-conjugated: CD20, CD8, CD45, HLA-DR, and all IgG controls from Becton Dickinson (BD, San José, CA, USA), FITC conjugated: CD15, CD61, anti-lambda, anti-Tdt, anti-IgM, PE-conjugated CD33, CD10, CD2 and anti-kappa, from DAKO (Glostrup, Denmark), PE-conjugated: anti-GPA and CD34, from Immunotech, (Marseille, France), PE-Cy5 conjugated: CD13, CD19, CD33 from Caltag Laboratories (San Francisco, CA, USA) and FITC conjugated CD65 from An-der-Grub Biosearch (Vienna, Austria).
Sample preparation:
Bone marrow aspirates were collected in heparin anticoagulant tubes, directly diluted 1:1 (vol/vol) with 0.9% NaCl and maintained at room temperature (RT) until processed (not longer than 24 h). A stain and then lyse/wash technique was used: 100 l of BM cell suspension (at least 1 × 10 6 nucleated cells) were incubated for 10-15 min (RT, in the dark) with saturating amounts of triple combinations of Mab. After incubation with Mab, 2 ml of FACS lysing solution (BD, diluted 1/10 in distilled water) were added and samples were incubated for another 5 min (all incubations at RT, in the dark). After lysis, the cells were centrifuged (5 min, 500 g), washed in 2 ml PBS and suspended in 0.5 ml of PBS. In Mab combinations including cytoplasmic (cy) or nuclear (n) antigens the staining for surface markers (as above) was followed by a fixation and permeabilization with 800 l Permeafix ((OPM), Ortho, Raritan, NY, USA, diluted 1:1 (vol/vol) with distilled water, 30 min) or with 100 l solution A, Intrastain (DAKO, 15 min. After OPM or Intrastain fixation the cells were centrifuged (5 min, 500 g) and washed with 2 ml PBS. A further incubation with Mab to cy or n antigens followed for 30 min in OPM prepared samples and 15 min in Intrastain-processed samples (together with 100 l of solution B). Finally, the cells were washed in 2 ml PBS and suspended in 0.5 ml PBS. Both intracellular procedures gave equal results in detecting nTdT, cyCD3 and cyIgM. In all cases isotype-matched immunoglobulins with no reactivity against a Percentages of patients with B-precursor ALL and T-ALL, followed using given Mab combination, respectively.
BM cells and the CD3-FITC/CD4-PE/CD8-PERCP combination were used as negative and positive controls, respectively.
Data acquisition and analysis:
Data acquisition was performed using FACScan or FACS-Calibur flow cytometer (BD), equipped with Lysis II and/or Cell Quest software programs. The light scatter characteristics and the auto-fluorescence levels of normal PB lymphocytes were used as reference values for instrument settings. At diagnosis a total of 15 × 10 3 non-gated events were acquired. At follow-up, a two-step acquisition procedure was applied. The first step was as above and in the second step a live gate (LG) was set on the basis of lineage marker expression (CD19 for B precursor and CD7 or cyCD3 for T ALL) and low/intermediate side scatter (SSC) characteristics (lymphoid scatter). The total numbers of cells passing the flow cytometer were recorded for each LG acquisition.
Data analysis was performed with Paint-a-Gate Pro (BD) software. The expression of the other markers was analyzed within CD19
+ or CD7 + alt cyCD3 + /lymphocyte SSC gate in order to determine the presence of cell subsets with aberrant marker expression (Figure 2) . 30, 32, 39 The fluorescence intensity of B and T cell markers observed in normal lymphocytes present in each analyzed sample was used as the reference value for describing the intensity of antigen expression in leukemic blasts. Thus, cells expressing markers with higher intensity than corresponding normal cells were considered as 'bright' (over-expression) and cells with negative or low expression as 'dim' (under-expression). A cluster of at least 10-20 events with aberrant marker expression and adequate scatter characteristics was considered as MRD ( Figure 2) . Therefore, in all cases where more than 10 5 cells passed the flow cytometer, the sensitivity of MRD detection was at least 1 cell per 10 4 BM cells. The percentages of cells with MRD phenotype in the bone marrow were determined in two different manners: (1) By dividing the numbers of events with MRD phenotype found in the samples by the recorded total numbers of cells passing the flow cytometer; (2) by expressing the percentages of aberrant cells as fractions of B or T cells collected by LG acquisition and finally calculating the percentage of aberrant MRD cells in the total BM using the percentages of B cells or T cells from the first acquisition of 15 × 10 3 events from the total BM. 29 Paired t-test showed no significant differences between the two methods of MRD calculation (P Ͼ 0.05).
In each follow-up sample all applied marker combinations were evaluated. In most follow-up samples all triple staining gave concordant results. In samples with some discrepancy the marker combinations with most aberrant features were considered as MRD value at each follow-up time. No changes in immunophenotype affecting followed aberrant patterns were observed.
Quality of samples:
In total, 309 follow-up BM samples were analyzed (median five samples/patient). The numbers of follow-up samples obtained at different time-points of treatment and in various risk-groups are presented in Table 2 . The numbers of cells that passed the flow cytometer during LG analysis of each Mab combination from all follow-up samples were recorded. In 82% of the samples more than 10 5 events were analyzed, which gave a sensitivity of MRD detection of at least one leukemic cell in 10 000 BM cells (10 −4 ). All samples with less than 10 5 events per LG analysis were taken during or immediately after the first induction (18% of total). In 37 samples (12%) more than 10 6 cells passed the flow cytoLeukemia meter giving a sensitivity of detection 10 −5 . There were no significant differences between SR, IR and VHR/HR treatment groups when the numbers of analyzed cells at various timepoints were considered. The numbers of cells analyzed did not differ dependent on immunologic subtype of leukemia, or between patients who relapsed and those who remain in CCR.
The contamination by peripheral blood (PB) was evaluated using the recorded information on percentages of T cells and erythropoietic precursor cells (GPA+) in the BM sample. Samples where percentages of T cells exceeded 20% and GPA+ cell content was low (under 15%) were considered as significantly blood contaminated and not as an empty bone marrow with early regeneration. These percentages were previously determined as the upper limit of the T cell content and GPA+ cell content found in samples from the normal BM (Ref. 32 and own unpublished observations). Considerable blood contamination was detected in 21 of 50 samples (42%) taken during the first induction (MRD 1) and in 13 of 49 (26%) taken immediately after the first induction (MRD 2). All but two BM samples taken later on during the follow-up had the results within limits for patient age.
Dilution experiments
To further investigate the sensitivity of the applied method a series of dilution experiments was performed. Leukemic blasts from diagnostic samples from patients with B-precursor ALL were admixed to regenerating normal BM samples from age-matched leukemia patients under treatment. A series of dilutions 1:1000, 1:10 000 and 1:100 000 was then studied by a routine MRD protocol (see above). The results clearly showed the sensitivity of detection 10 −5 for all tested Mab combinations, provided the leukemic cells showed aberrant marker expression confined to 'empty spaces'. 30, 32, 39 Similar sensitivity was achieved for T-ALL using Mab combination TdT/CD5/CyCD3. The examples of dilution experiments are illustrated in Figure 3 .
Statistical analysis
For statistical evaluation, either the individual MRD values were used or the samples were categorized according to high Ն0.01% or low Ͻ0.01% MRD levels.
To compare MRD levels at various time-points and in various patients categories non-parametric testing was used for two (Mann-Whitney U) or more (Kruskall-Wallis H) groups. The 2 test and when appropriate Fisher's exact tests were used to explore the association between categorized variables. Paired t-test was used to test difference between two applied analysis methods. Univariate and multivariate logistic regression method was used to explore the prognostic impact of MRD. The disease-free survival (DFS) curves were created using Kaplan-Meier method and compared using log-rank test. The P values were always two-sided and values Ͻ0.05 were regarded as statistically significant. The Statistical Package for Social Science, version 8.0 (SPSS) was used for statistical calculations.
Results
MRD levels in follow-up samples at different timepoints of treatment
Percentages of follow-up samples with MRD levels Ն0.01% and Ͻ0.01% of BM cells at different time-points of treatment for patients with no relapse in the BM and for patients with recurrence in the BM are shown in Table 2 . In the group of patients with no BM recurrence the percentages of samples with MRD values Ն0.01% decreased with time in all treatment groups. The majority of relapse patients had MRD values Ն0.01% at all studied time-points (a significantly higher frequency by comparison to patients with no BM relapse, P Ͻ 0.001). The only relapse patient who had MRD level Ͻ0.01% at end of treatment (time-point MRD6), showed an increase to MRD level 0.02% after 3 months without treatment (timepoint MRD7, Table 2 ).
When individual MRD values were considered, significantly higher MRD levels were found in T-ALL patients by comparison to B-precursor ALL patients at three time-points: MRD1 (P Ͻ 0.005), MRD2 (P Ͻ 0.05) and MRD3 for the IR/HR group (P Ͻ 0.05). (individual MRD values not shown). At MRD1 time-point, the significant difference between T and B ALL groups was also found when patients were categorized into groups with high and low MRD values (cut-off 0.01%) (Figure 4 ). No differences in MRD values in follow-up samples from patients with different immunologic categories of B precursor ALL were found at different time-points of treatment. When individual MRD values obtained in various treatment groups at various time-points were compared, samples from the IR and HR patients showed significantly higher MRD levels than SR group at the MRD1 time-point (P Ͻ 0.05). Also, samples from the IR group had significantly higher values than samples from the SR group at MRD5 time-point (P Ͻ 0.05). At MRD3 time-point, the MRD levels were higher in the IR group than in the HR group (P Ͻ 0.05) (individual MRD values
Flow cytometric detection of MRD and prognosis in childhood ALL
E Björklund et al 143
Figure 3
Dilution experiments showing sensitivity of MRD detection with two most frequently applied Mab combinations: CD34FITC/CD19 PE/CD45PerCP and TdT FITC/CD10PE/CD19 PE/Cy5. ALL blasts were diluted with regenerating normal (MRD-free) BM sample from an agematched leukemia patient under treatment (time-point MRD3, 3 months after diagnosis). Plots a and g show that leukemic blast displayed aberrant pattern of antigen expression (red dots). 30, 39 Plots b and h show normal BM pattern before CD19/SSC gating. B cells are painted in green. Plots c and i show normal antigen expression pattern after CD19/SSC gating. Plots d, e, f and j, k, l show dilution series (1:1000, 1:10 000, 1:100 000) for two studied Mab combinations, respectively. Up to 600 000 cells were acquired from each cell sample. Leukemic blasts could be detected in all dilutions (red dots).
Figure 4
Frequency of samples with high (Ն0.01%, black) and low (Ͻ0.01, gray) MRD levels at time-points MRD1, MRD2 and MRD3 for T-ALL and B-precursor ALL. The risk-groups have been separated at the MRD3 time-point due to the difference in time from the start of therapy (see Figure 1) . The frequency of samples with high MRD value was significantly higher in T-ALL at MRD1 time-point (P = 0.034), but not at other time points (P Ͼ 0.05).
not shown). All other pair-wise comparisons did not give any significant differences.
Changes in MRD levels at different time-points of treatment could also be classified as four types of response curves (Quick (Q) 1, Q2, Slow (S) 1 and S2) as follows (Figure 5a-d ):
• Q1, if MRD2 level was Ͻ0.01% and then under detection limit (38 patients) • Q2, if MRD2 level Ͻ0.01% and then between 0.01 and 0.001% (4 patients) • S1, if MRD2 level Ն0.01% but then under detection limit (7 patients) • S2, if MRD2 level Ն0.01% and then above 0.01% at most follow-up time-points (11 patients).
In one patient the response curve type could not be evaluated due to early relapse.
Prognostic significance of MRD levels
All children achieved morphological remission after the first induction treatment. Relapse of ALL was demonstrated in nine of 61 children (14.75%). In seven patients (1 null-ALL, 3 c-ALL and 3 pre B-ALL) the recurrence was demonstrated in the BM after the end of treatment (26, 30, 38, 39, 46 , 47 and 52 months after diagnosis). Two patients demonstrated extramedullary relapses in testis: one patient with T-ALL after only 3 months of treatment and the other patient (with c-ALL) 67 months after diagnosis. The first patient later showed a second recurrence in the BM, the latter patient did not show any signs of BM relapse and remains in remission.
There was no significant difference in outcome when the whole B precursor group and T-ALL group were compared. The immunologic category significantly influenced outcome ( 2 test, P = 0.017), which could depend on relatively high frequency of relapses in patients with pre-B ALL immunologic subtype (three of seven patients) or low frequency of relapses in common ALL group (three of 43 patients). There was no statistical difference in frequency of relapses depending on the treatment group or on cytogenetic category. There was a significantly higher relapse risk for patients with MRD levels Ն0.01% at MRD2 and MRD3 time-points (P = 0.034 and P = 0.027, respectively) and especially, at both time-points (P = 0.007) (for frequencies see Table 2 ).
The mean DFS for children who suffered relapse of ALL was 38.6 months (median 39 months, range 3-67 months). For children in CCR the mean follow-up time was 51 months (median 53 months, range 26-71 months). Patients with MRD levels Ն0.01% under induction treatment (MRD1), after induction (MRD2) and at the end of treatment (MRD6) showed significantly lower DFS (P = 0.0375, P = 0.0006 and P Ͻ 0.0001, respectively, Figure 6a, b, c) .
There was no significant difference in DFS when the whole B precursor group and T-ALL group were compared, but patients with B-precursor ALL of pre-B (cyIgM+) category showed significantly lower DFS (P = 0.0028). Multivariate analysis was performed using logistic regression model including: age, WBC, risk-group, cytogenetic group, immunologic subtype and MRD categorized in high (Ն0.01%) vs low (Ͻ0.01%) MRD levels at MRD2 and MRD3 time-points. High MRD levels (P = 0.0338) were together with immunologic subtype (P = 0.0438) the only independent variables influencing prognosis. The results from bivariate model showed that the group of patients with high MRD levels at MRD2 and Figure 6 (a-c) Disease-free survival curves of patients with ALL categorized according to MRD levels at various follow-up time points show significantly worse DFS for patients with MRD levels Ն0.01%. MRD3 time-points had 29-fold higher relapse risk when compared to other patients, and patients with pre-B immunologic subtype had 14-fold higher risk of relapse than the remainder.
The differences in total survival were not evaluated due to low number of deaths. Three patients died since the beginning of this study: one patient died in CR due to hemolytic-uremic syndrome (HUS) and two patients due to relapse of ALL.
Leukemia
Infant leukemia patients
Three infants (2, 7 and 9 months old) were diagnosed with null ALL with t(4;11) translocation and treated according to the infant leukemia protocols. All three patients were followed using Tdt/CD34/CD19 and CD15/CD34/CD19 marker combinations. Two children suffered relapse, 5 and 25 months after diagnosis, respectively. Both these patients died of leukemia. The MRD levels in these patients were above 0.01% at all time-points and the 'responder curves' were classified as S2 (Figure 5d ). The third infant leukemia patient is in CCR, 28 months after diagnosis and the curve type was evaluated as S1 (Figure 5c ), with MRD level under 0.01% after 10 months of treatment and under detection levels at the end of treatment.
Discussion
Our study reports the results of MRD follow-up in ALL patients by flow cytometry using protocols based on the experience of BIOMED I Concerted Action 'Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation'. The specific aberrant patterns of antigen expression in ALL have been characterized and the patterns found were suitable for MRD detection. The followup samples were obtained from a similarly treated cohort of consecutive patients with childhood ALL. Patients with MRD levels Ն0.01% at follow-up time-points during and after first induction and at the end of treatment had significantly lower disease-free survival by comparison to patients with MRD values Ͻ0.01%. Nine of 11 patient with recurrence in the BM (two patients with infant leukemia included) showed under treatment persisting MRD levels Ն0.01% of BM cells.
The sensitivity of both molecular and immunologic MRD detection methods depends on the numbers of cells analyzed and on the probes applied. For optimal PCR and FC results it is imperative that the BM specimen contain a large number of viable mononuclear cells and that blood contamination is low. Also, sample preparation and live gate acquisition should be performed within 24 h. If the samples have remained unprocessed longer, changes in FSC/SSC pattern and increasing population of dying/apoptotic cells can interfere with the interpretation. A BM sample taken from a typical patient with acute leukemia during treatment yields up to 5 × 10 7 mononuclear cells, but technical constraints limit the number of cells available for LG analysis. 40 In our study sensitivity of at least 10 −4 was obtained in 82% of samples where the yield of cells in LG analyses was over 10 5 . In 12% of samples the cell yield was higher than 10 6 resulting in sensitivity 10 −5 . At the first two follow-up time-points (during and at the end of the first induction) there were fewer cells available when compared to the other time-points. This may be due to the very intensive chemotherapy during this phase of treatment and delayed recovery after the bone marrow replacement by leukemia. 38 With techniques, such as the LG approach, MRD detection levels by FC have increased considerably and reached sensitivity comparable to molecular methods. In both our previous study and other studies that applied in the same follow-up BM samples PCR based MRD detection and FC, consistent results were obtained. 41, 42 One of the difficulties in FC application for MRD studies is a lack of leukemia-specific antigens. However, thorough studies of diagnostic samples and comparison with normal BM patterns of antigen expression make it possible to find suitable marker combinations. In the present study we were able to perform FC MRD follow-up in 97% of the ALL cases. In 79% of cases at least two aberrant features were followed. This high level of detection of abnormal antigen expression patterns is due to the work and experience of the BIOMED Concerted Action on MRD. Our knowledge of immunophenotypic patterns of normal cells in BM has improved and abnormal patterns displayed by leukemic cells could more easily be identified. 30, 32, 39 It is of importance that all aberrant phenotype patterns found at diagnosis, even those that are present only in subsets of leukemic cells are applied in follow-up studies. At relapse of ALL, the changes in the expression in individual markers may occur but are less common than in acute myeloid leukemia. 43, 44 These changes usually do not affect antigens involved in the definition of the leukemia-associated phenotypes. In previous studies and in our experience at least one aberrant pattern remained stable at relapse. Moreover, studies of normal B cell precursor differentiation patterns in regenerating bone marrow may facilitate distinction between MRD and B cells regenerating after chemotherapy. 45 In some patients recurrences may develop even from very small populations present at diagnosis, which may be interpreted as the phenotype switch. This was the case with one of our T-ALL patients, who demonstrated AML phenotype at relapse and during follow-up did not show TdT/cyCD3 positive population but persisting small CD34 + /CD7 + /CD33(dim) population. The analysis of clonal rearrangements of IgH and TcR genes by PCR and sequencing identified in samples from diagnosis and relapse identical rearrangements in IgH and TcR V␥2. The rearrangement in TcR V␥9 found at diagnosis was replaced at relapse by rearrangement in TcR V␥4 (own unpublished observations).
One of the final goals of MRD studies is to obtain more precise evaluation of effectiveness of treatment in order to design individual post-remission therapies and to detect impending relapses prior to clinical manifestations. Individual approach to treatment could reduce the risk of both relapses and therapy-related late effects. Our results obtained in a consecutive cohort of similarly treated patients suggest that FC follow-up may easily create 'treatment response curves' for clinical use.
Some issues are raised, eg the importance of the sensitivity of the MRD detection techniques, clinically significant levels of MRD predictive of clinical outcome, the relationship of MRD levels with leukemia subtype and what kind of therapy intensification could improve the outcome for patients with high MRD levels. Many authors agreed that MRD levels of 0.01% or higher at the end of first induction are associated with high relapse risk. 11, [46] [47] Our study shows similar incidence of MRD at the end of first induction as other European studies applying molecular methods. 14, 21, 24, 47 Other studies where PCR assays of very high sensitivity were used, concluded that almost all children with ALL had residual leukemia detected at the end of induction, early intensification and consolidation therapies, 26 suggesting that MRD levels lower than 10 −5 may not be clinically relevant. When discussing sensitivity and reproducibility of the method it must not be forgotten that other factors such as sampling site (uneven distribution of the disease in the BM 'hot spots') and peripheral blood contamination may influence the results. Moreover there may be differences in the kinetics of MRD resolution depending on patient age, 47 type of treatment, 24, 46 and even between different leukemic clones. 48 The 
